Core Insights - The company reported a significant decline in revenue and net profit for the first half of 2025, with revenue at 219 million yuan, down 27.22% year-on-year, and a net profit of -116 million yuan compared to -27 million yuan in the same period last year [1] - The decrease in performance is attributed to delayed customer demand, slow bidding processes, tightened hospital budgets, increased industry competition, and rising implementation costs due to project delays [1] - The company is a leader in electronic medical records and anticipates that AI healthcare demand will enhance its value proposition in the future [1] Financial Performance - The gross margin for the first half of 2025 was 20.52%, a decrease of 27.51 percentage points, primarily due to extended project delivery cycles increasing cost pressures [2] - The sales, management, and R&D expense ratios were 19.35%, 17.52%, and 29.61%, respectively, with increases of 2.95, 1.31, and 4.26 percentage points, driven by rigid personnel costs and increased R&D investments [2] - R&D investment accounted for 43.36% of revenue, up 2.64 percentage points year-on-year, reflecting the company's commitment to enhancing its core technology and long-term competitiveness [2] Product Development - The company upgraded its core product, the electronic medical record system, integrating AI capabilities through the development of the Jiahe domain-specific medical model [3] - A new generation of intelligent electronic medical record platform (V7) was launched, featuring a microservices and B/S architecture, achieving full-stack compatibility and deep integration with the Jiahe medical model [3] - The company has accelerated the commercialization of AI products, with four core solution scenarios implemented in several large tertiary hospitals [3] Competitive Advantage - The company is enhancing its AI capabilities by upgrading its data center products into a multimodal intelligent platform, improving data governance and efficiency [4] - The integration of AI in emergency medical services has led to the development of a comprehensive platform that generates treatment plans and predicts mortality risk based on extensive data training [4] - The focus is on empowering clinical, research, teaching, and management scenarios with AI to enhance the competitiveness of medical products [4] Profit Forecast and Valuation - The profit forecast remains unchanged, with expected net profits of 44 million, 102 million, and 191 million yuan for 2025-2027 [5] - The company is assigned a target price of 44.48 yuan based on a 60x 2026 PE ratio, reflecting its strengthened competitiveness in the medical AI sector [5]

证券研究报告 25H1 毛利率短期承压，研发投入持续提升 25H1 公司毛利率为 20.52%，同比下降 27.51pct，主要由于部分客户的项 目实施交付周期延长，导致成本端压力增大。销售/管理/研发费率分别为 19.35%/17.52%/29.61%，同比+2.95/+1.31/+4.26pct，费用率提升主要是 由于人员成本支出偏刚性以及公司加大研发投入。公司保持高研发投入，持 续迭代医疗 AI 技术与产品，增强核心技术壁垒与长期竞争力，25H1 研发投 入占收入比为 43.36%，同比提升 2.64pct。根据 IDC 数据，公司 2024 年 在电子病历细分市场排名第一，连续第 11 年蝉联市场第一。 重磅升级核心产品电子病历，深度融合 AI 能力 公司自主研发嘉和垂域医疗大模型，25 年 4 月，"北医三院-嘉和美康医学 信息人工智能联合研发实验室"发布"三院灵智"智能体系。公司 25 年初 推出新一代智能电子病历平台（V7），采用微服务与 B/S 架构，实现国产 化全栈适配，深度融合嘉和医疗大模型，构建多层病历生成、医保联动临床 路径及病案内涵质控，实现深度、广度、效率、质量全面领先。在技术突破 ...